NCT06084988 - A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

November 8, 2024

Study Completion Date

April 7, 2025

Conditions

Osteo Arthritis Knee

Interventions

BIOLOGICAL

Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)

50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection

Trial Locations (1)

Unknown

RECRUITING

Burjeel Medical City, Abu Dhabi